Rare Disease & Autism Information
Finding trustworthy health information shouldn't be this hard. Here you'll find research, practical guides, and advocacy tools on rare disease, pediatric ALS, and autism. They're here to help families prepare for appointments and ask better questions, and to help clinicians, educators, and partners understand the families they serve. Diagnosed or still searching, every child matters here.
The Scale of the Challenge
Rare diseases are far more common than most people realize, and they disproportionately affect children.
By the Numbers
Rare diseases affect an estimated 25-30 million people in the United States. Roughly 1 in 10.
About 50% of all people living witha. rare disease are children.
The average "diagnostic odyssey" (the time from first symptoms to an accurate diagnosis) often lasts 4-8 years or longer.
How Common Are Rare Diseases?
More than 7,000 known rare diseases. 25 to 30 million people in the U.S.
Children Are Hit Hardest.
About 70% begin in childhood.
30% of children with a rare disease won't reach age 5.
Why Answers Take So Long.
Roughly 80% of rare diseases are genetic or have a genetic component. Specialists and genetic testing are often far from rural families.
Many children - especially those in rural communities or from underrepresented racial and ethnic backgrounds - face even greater barriers. Specialist care and advanced genetic testing are often concentrated in urban centers, and some children remain undiagnosed for years. These gaps in access and representation are exactly why Melanin Children Matter focuses on accelerating equitable diagnosis and supporting families who are too often left behind.
The Paradox of Rare
Despite the scale of the problem, progress remains uneven.
The Human Cost
95% of rare diseases have no FDA-approved treatment.
~$1 trillion annual economic burden of rare diseases in the United States.
Up to $500,000 in avoidable costs per patient linked to delayed diagnosis (medical expenses & lost productivity over the diagnostic journey).
Meanwhile...
The Growing Market
50% of new FDA drug approvals receive Orphan Designation.
~20% of global prescription drug sales come from rare disease therapies.
13% yearly market growth.
~$600 billion projected market by 2034
These numbers reveal a clear paradox:
An enormous unmet need and high human cost exist alongside a rapidly growing commercial market.
For medically underrepresented children - including those in rural and underserved communities - the gaps in diagnosis, research inclusion, and timely care are even wider.
Sources:
EveryLife Foundation for Rare Diseases (economic burden and delayed-diagnosis studies), U.S. Food and Drug Administration, National Organization for Rare Disorders (NORD), GAO reports, and related market analyses and peer-reviewed literature on prevalence, pediatric impact, diagnostic delay, and research representation.
Applied behavior analysis (ABA) is an evidence-based treatment to help children with autism learn new skills and stop destructive behaviors, like hurting themselves. However, there are a lot of different approaches to ABA. It is controversial because the way the therapy works and the training of the therapists can vary a lot. Learn what you should know before exploring ABA for your child.
In this peer reviewed journal article, published in the journal, Brain, you'll learn about various genetic mutations that result in a family of disorders called "Hereditary Motor Neuropathies." The article discusses prevalence and diagnostic criteria in the age of next generation genetic sequencing.
The world of rare disease is expansive, with over 10,000 diagnoses that fit the criteria. What unique challenges does a rare diagnosis present for a patient and family? What resources are there to help cope and thrive in spite of a rare diagnosis? This Medline Plus page provides a number of resources to help you answer questions like these and feel empowered.